Cargando…

Direct-actng antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital

INTRODUCTION: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Six different genotypes (GT) of HCV (genotypes 1-6) have been identified. The genotype is clinically relevant since the majority of current direct antiviral agents (DAA´s) do not have pangenotypic efficacy. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	del Rio-Valencia, Juan Carlos, Asensi-Diez, Rocío, Villalobos-Torres, Lorenzo, Castillo, Isabel Muñoz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedad Española de Quimioterapia 2018
Materias:	Original
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166256/ https://www.ncbi.nlm.nih.gov/pubmed/29771105

Ejemplares similares

Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital
por: del Rio-Valencia, Juan Carlos, et al.
Publicado: (2018)

Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C
por: del Rio-Valencia, Juan Carlos, et al.
Publicado: (2019)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study
por: Muñoz-Hernández, Rocío, et al.
Publicado: (2020)

Diagnóstico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel
por: Asensi-Diez, Rocío, et al.
Publicado: (2019)

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district
por: Polilli, Ennio, et al.
Publicado: (2016)

Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
por: Hawsawi, Nahed Mohammed, et al.
Publicado: (2023)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis
por: Yen, Hsu-Heng, et al.
Publicado: (2022)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

New Antiviral Agents for Hepatitis C
por: Pawlotsky, Jean-Michel
Publicado: (2012)

Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
por: Minosse, Claudia, et al.
Publicado: (2018)

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
por: Xiao, Fei, et al.
Publicado: (2014)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents
por: Estefan, Sergio, et al.
Publicado: (2021)

Hepatitis C-related membranoproliferative glomerulonephritis in the era of direct antiviral agents
por: Abdelhamid, Walid Ahmed Ragab, et al.
Publicado: (2021)

The care cascade for hepatitis C virus and prognosis of chronic hepatitis C patients treated with antiviral agents in a tertiary hospital
por: Yoo, Sung Hwan, et al.
Publicado: (2023)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
por: Mei, Yong-yu, et al.
Publicado: (2020)

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus
por: Wang, Ye, et al.
Publicado: (2015)

Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis
por: Liu, Jiaye, et al.
Publicado: (2019)

Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study
por: Kang, Yeo Wool, et al.
Publicado: (2021)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2019)

Glycyrrhizin as antiviral agent against Hepatitis C Virus
por: Ashfaq, Usman A, et al.
Publicado: (2011)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China
por: Li, Zhao, et al.
Publicado: (2017)

Antiviral agents in the critically ill child
por: Munoz, Flor M.
Publicado: (2000)

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis
por: Suwanthawornkul, Thanthima, et al.
Publicado: (2015)

Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
por: Mohamed, Hala, et al.
Publicado: (2022)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients
por: Gottlieb, Robert L., et al.
Publicado: (2018)

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
por: Shirahashi, Ryosaku, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kaqkv31kiat2tn1e1d8sqlj768